A Phase 3 interventional study of Genotropin and somatrogon in Growth Hormone Deficiency, sponsored by Pfizer. Completed at 32 sites in 5 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-10-14.
Sponsored by Pfizer · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 24th largest by enrollment, is one of 2 that started in 2019, is one of 23 in phase 3, and was the 56th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 21–55
Baylor College of Medicine · Sites in United States
Ages 18–64
Changchun GeneScience Pharmaceutical Co., Ltd.
Ages 6 mo–17 yrs
By country, each count listing its studies:
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 24 · Phase 4 19
First in 1997; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.
Median enrollment 66 across the 60 interventional studies. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 60 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
17 studies in Dwarfism, Pituitary by Pfizer: 1 open now, 2 under way, none of them phase 3. Of 14 finished, 8 (57%) have results posted.
Among the 17 studies in Dwarfism, Pituitary by Pfizer, this one is the 7th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 7 in phase 3, and was the 14th registered.
Pfizer’s Dwarfism, Pituitary studies by the year they started, since 1997.
2 of the studies testing Human Growth Hormone in Dwarfism, Pituitary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05355272Baylor College of MedicineGrowth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 17 in Dwarfism, Pituitary:
This tab as a report to print or save as PDF → With an account.
This is an open label randomized 24 week crossover trial assessing the treatment burden of a weekly growth hormone injection regimen (somatrogon) compared to a daily growth hormone injection regimen (Genotropin). Approximately 90 children with growth hormone deficiency who have been stable on treatment with daily Genotropin will be enrolled.
Subjects will be randomized to one of two sequences, either 12 weeks of continued treatment with daily Genotropin followed by 12 weeks of treatment with weekly somatrogon, or 12 weeks of treatment with weekly somatrogon followed by 12 weeks of treatment with daily Genotropin. Subjects will have study visits at Baseline, Weeks 6, 12, 18, and 24. Subjects will also be followed up by phone 8 to 12 days after each treatment period begins (Week 1 and Week 13). Subjects and caregivers (as a Dyad) will complete questionnaires assessing treatment burden at baseline and at the end of each 12 week treatment period. All subjects/caregivers will receive a follow up phone call at Week 28.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genotropin to somatrogon
Drug: Genotropin · Drug: somatrogon
somatrogon to Genotropin
Drug: Genotropin · Drug: somatrogon
Genotropin (dose \[mg\] at time of enrollment) given subcutaneously once daily
0.66 mg/kg/week given subcutaneously once weekly
Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire
Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).
Time frame: Baseline
Total Score Related to Overall Life Interference Assessed at Week 12, Using DCOA 1 Questionnaire
Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).
Time frame: Week 12
Total Score Related to Overall Life Interference Assessed at Week 24, Using DCOA 1 Questionnaire
Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).
Time frame: Week 24
Total Score Related to Overall Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire
Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).
Time frame: Baseline up to Week 24
Total Score Related to Pen Ease of Use Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked 5 questions from Section I of the Injection Pen Assessment Questionnaire (IPAQ) patient-reported outcome (PRO) tool related to pen ease of use and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to pen ease of use was sum of all 5 questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
Time frame: Baseline, Week 12, Week 24
Total Score Related to Pen Ease of Use by Treatment in Overall Study, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked 5 questions from Section I of the IPAQ PRO tool related to pen ease of use and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to pen ease of use was sum of all 5 questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
Time frame: Baseline up to Week 24
Total Score Related to Ease of the Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to ease of the injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
Time frame: Baseline, Week 12, Week 24
Total Score Related to Ease of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to ease of the injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
Time frame: Baseline up to Week 24
Total Score Related to Convenience of the Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 7-point scale: 1=extremely convenient to 7=extremely inconvenient. The total score related to convenience of injection schedule ranged from 1 to 7; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
Time frame: Baseline, Week 12, Week 24
Total Score Related to Convenience of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 7-point scale: 1=extremely convenient to 7=extremely inconvenient. The total score related to convenience of injection schedule ranged from 1 to 7; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
Time frame: Baseline up to Week 24
Total Score Related to Satisfaction With Overall Treatment Experience Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant satisfaction with treatment and used a 5-point scale: 1=very satisfied to 5=very dissatisfied. The total score related to satisfaction with overall treatment ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
Time frame: Baseline, Week 12, Week 24
Total Score Related to Satisfaction With Overall Treatment Experience by Treatment in Overall Study, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant satisfaction with treatment and used a 5-point scale: 1=very satisfied to 5=very dissatisfied. The total score related to satisfaction with overall treatment ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
Time frame: Baseline up to Week 24
Total Scores Related to Willingness to Continue Injection Schedule Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant willingness to continue treatment and used a 5-point scale: 1=extremely willing to 5=not at all willing. The total score related to willingness to continue injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
Time frame: Baseline, Week 12, Week 24
Total Scores Related to Willingness to Continue Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant willingness to continue treatment and used a 5-point scale: 1=extremely willing to 5=not at all willing. The total score related to willingness to continue injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
Time frame: Baseline up to Week 24
Total Scores Related to Injection Signs and Symptoms for Participants Aged 8 Years and Above Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participants (8-17 years old). Participants were asked 4 questions from Section I of the IPAQ PRO tool related to participant's injection signs and symptoms and used a 11-point scale: 0=no pain to 10=worst possible pain; 0=no stinging to 10=worst possible stinging; 0=no bruising to 10=worst possible bruising; and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for injection signs and symptoms meant a better outcome.
Time frame: Baseline, Week 12, Week 24
Total Scores Related to Injection Signs and Symptoms for Participants Aged 8 Years and Above by Treatment in Overall Study, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participants (8-17 years old). Participants were asked 4 questions from Section I of the IPAQ PRO tool related to participant's injection signs and symptoms and used a 11-point scale: 0=no pain to 10=worst possible pain; 0=no stinging to 10=worst possible stinging; 0=no bruising to 10=worst possible bruising; and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for injection signs and symptoms meant a better outcome.
Time frame: Baseline up to Week 24
Total Scores Related to Assessment of Signs, Completed by Caregiver for Children Aged <8 Years Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver for children under 8 years. Participants were asked 2 questions from Section I of the IPAQ PRO tool related to participant's assessment of signs and used a 11-point scale: 0=no bruising to 10=worst possible bruising and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for assessment of signs meant a better outcome.
Time frame: Baseline, Week 12, Week 24
Total Scores Related to Assessment of Signs, Completed by Caregiver for Children Aged <8 Years by Treatment in Overall Study, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver for children under 8 years. Participants were asked 2 questions from Section I of the IPAQ PRO tool related to participant's assessment of signs and used a 11-point scale: 0=no bruising to 10=worst possible bruising and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for assessment of signs meant a better outcome.
Time frame: Baseline up to Week 24
Total Scores Related to Caregiver Life Interference, Including Family Life Interference Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver. Participants were asked 13 questions from Section I of the IPAQ PRO tool related to caregiver life interference and used a 5-point scale: 1= never to 5= always. The total score ranged was sum of scores from all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for caregiver and family life interference meant less life interference (a better outcome).
Time frame: Baseline, Week 12, Week 24
Total Scores Related to Caregiver Life Interference, Including Family Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver. Participants were asked 13 questions from Section I of the IPAQ PRO tool related to caregiver life interference and used a 5-point scale: 1= never to 5= always. The total score ranged was sum of scores from all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for caregiver and family life interference meant less life interference (a better outcome).
Time frame: Baseline up to Week 24
Total Scores Related to Missed Injections Assessed at Baseline, Week 12 and Week 24, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to number of missed injections (daily or weekly administration) during past 4 weeks. The total scores ranged from 0 to 31 for daily administration (Genotropin) and from 0 to 5 for weekly administration (Somatrogon). All scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for missed injections meant a better outcome.
Time frame: Baseline, Week 12, Week 24
Total Scores Related to Missed Injections by Treatment in Overall Study, Using DCOA 1 Questionnaire
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to number of missed injections (daily or weekly administration) during past 4 weeks. The total scores ranged from 0 to 31 for daily administration (Genotropin) and from 0 to 5 for weekly administration (Somatrogon). All scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for missed injections meant a better outcome.
Time frame: Baseline up to Week 24
Number of Participants as Per Responses to Choice of Injection Pen Assessed at Week 24, Using DCOA 2 Questionnaire
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "If you were given the choice between the daily growth hormone injection pen and the weekly growth hormone injection pen, which pen would you choose?" Response was: 1) the daily injection pen (Genotropin) or 2) the weekly injection pen (Somatrogon).
Time frame: Week 24
Number of Participants as Per Responses to Preferred Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule do you prefer overall?" by choosing from any 1 option from: 1) prefer the weekly injection schedule (Somatrogon); 2) prefer the daily injection schedule (Genotropin); 3) no preference.
Time frame: Week 24
Number of Participants as Per Responses to Convenience of the Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule was more convenient overall?" by choosing from any 1 option from: 1) weekly injection schedule was more convenient (Somatrogon); 2) daily injection schedule was more convenient (Genotropin); 3) no difference.
Time frame: Week 24
Number of Participants as Per Responses to Ease of Following Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule was easier to follow overall?" by choosing from any 1 option from: 1) easier to follow weekly injection schedule (Somatrogon); 2) easier to follow daily injection schedule (Genotropin); 3) no difference.
Time frame: Week 24
Number of Participants as Per Responses to Pen Ease of Use Assessed at Week 24, Using DCOA 2 Questionnaire
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "Which pen was easier to use?" from Section II of the IPAQ PRO tool. Question had 4 parts: preparing the injection pen (Part I), setting the dose (Part II), injecting the medicine (Part III) and storing the pen (Part IV). Participants/caregiver expressed their preference by choosing from any 1 option for each activity from: 1) weekly pen easier to use (Somatrogon); 2) daily pen easier to use (Genotropin); 3) no difference.
Time frame: Week 24
Number of Participants as Per Responses to Participant Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to participant life interference. Participants were assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). The participants expressed their preference by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference.
Time frame: Week 24
Number of Participants as Per Responses to Caregiver Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire
Caregivers of participants were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to caregiver life interference and were assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). Preference was expressed by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference. The caregivers responded for the participants, and in actual they respond to the number of participants only but per caregiver responses.
Time frame: Week 24
Number of Participants as Per Responses to Family Life Interference Assessed at Week 24, Using DCOA 2 Questionnaire
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/ caregiver were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to family life interference and assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). Preference was expressed by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference.
Time frame: Week 24
Number of Participants as Per Response to Benefit Relating to the Injection Schedule Assessed at Week 24, Using DCOA 2 Questionnaire
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "How beneficial was to take injections less often?" from Section II of the IPAQ PRO tool pertaining to benefit relating to the Injection schedule and used a 5-point scale: 1= extremely beneficial, 2= very beneficial, 3= moderately beneficial, 4= slightly beneficial and 5= not at all beneficial. Lower score of benefit relating to injection schedule meant a better outcome.
Time frame: Week 24
Number of Participants as Per Responses to Intention to Comply Assessed at Week 24, Using DCOA 2 Questionnaire
Participants/caregiver dyads were asked 4 questions "Which schedule would be better able to follow?" (Question 1), "Which schedule would be more likely to follow for a longer time?" (Question 2), "Which schedule would be better able to follow for a longer time?" (Question 3) and "Which schedule would be more likely to follow?" (Question 4) from Section II of the IPAQ PRO tool related to participant intention to comply with treatment. Options for each question were: 1) weekly injection (Somatrogon) 2) daily injection (Genotropin), or 3) no difference.
Time frame: Week 24
Patient Global Impression Severity-Impact on Daily Activities (PGIS-IDA) Score Assessed at Baseline, Week 12 and Week 24
The PGIS-IDA rated the severity of the impact on daily activities due to the treatment administration during the past 4 weeks on a 7-point scale (1= not present to 7= extremely severe). Scores were transformed from raw scores to a 0 to 100 scale. Lower scores meant less impact on daily activities (better outcome).
Time frame: Baseline, Week 12, Week 24
Patient Global Impression Severity-Impact on Daily Activities (PGIS-IDA) Score by Treatment in Overall Study
The PGIS-IDA rated the severity of the impact on daily activities due to the treatment administration during the past 4 weeks on a 7-point scale (1= not present to 7= extremely severe). Scores were transformed from raw scores to a 0 to 100 scale. Lower scores meant less impact on daily activities (better outcome).
Time frame: Baseline up to Week 24
Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Emergent Treatment Related AEs and SAEs
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Treatment-emergent AEs (TEAEs) were defined as events that occurred between first dose of study drug up to 35 days after last dose of study drug. Related TEAEs were those AEs who had relation to the study treatment and was judged by investigator.
Time frame: Baseline up to 35 days after last dose of study drug (up to 29 Weeks)
Number of Participants With Adverse Events According to Severity
AEs were assessed and categorized according to the severity as mild (did not interfered with participant's usual function), moderate (interfered to some extent with participant's usual function) and severe (interfered significantly with participant's usual function).
Time frame: Baseline up to 35 days after last dose of study drug (up to 29 Weeks)
Number of Participants With Discontinuation Due to Adverse Events (AEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. The discontinuations due to adverse events was defined for participants and reported in this outcome measure.
Time frame: Baseline up to 35 days after last dose of study drug (up to 29 Weeks)
Number of Participants With Laboratory Abnormalities
The laboratory abnormality parameters included Hematology: erythrocyte (Er.) mean corpuscular volume, Er. mean corpuscular hemoglobin:\<0.9\*lower limit normal (LLN), leukocytes:\<0.6\*LLN, lymphocytes:\<0.8\*LLN, neutrophils:\<0.8\*LLN, greater than (\>) 1.2\*upper limit normal (ULN), eosinophils, monocytes:\>1.2\*ULN. Clinical chemistry: bilirubin, direct bilirubin, indirect bilirubin:\>1.5\*ULN, gamma glutamyl transferase:\>3.0\*ULN, albumin:\>1.2\*ULN, blood urea nitrogen:\>1.3\*ULN, urate:\>1.2\*ULN, high-density lipoprotein (HDL) cholesterol:\<0.8\*LLN, potassium, magnesium:\>1.1\*ULN, phosphate:\>1.2\*ULN, bicarbonate:\<0.9\*LLN, creatine kinase:\>2.0\*ULN. Urinalysis: specific gravity:\>1.030, ketones, urine protein, urine hemoglobin, nitrite, leukocyte esterase:\>=1.
Time frame: Week 1 to Week 12, Week 13 to Week 24
Number of Participants With Positive Anti-Recombinant Human Growth Hormone (rhGH) Antibodies and Neutralizing Antibodies (NAb)
Blood samples were collected for determination of rhGH and NAb. The participants who tested positive for antibodies were reported.
Time frame: Baseline, Week 12, Week 24
Number of Participants With Positive Anti-Somatrogon Antibodies and Neutralizing Antibodies (NAb)
Blood samples were collected for determination of anti-somatrogon antibodies and NAb. The participants who tested positive for antibodies were reported.
Time frame: Baseline, Week 12, Week 24
| Milestone | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Started | 43 | 44 |
| Completed | 43 | 43 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event, not serious | 0 | 1 |
| Milestone | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Started | 43 | 43 |
| Completed | 43 | 42 |
| Not completed | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 1 |
| Milestone | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Started | 43 | 43 |
| Completed | 43 | 43 |
| Not completed | 0 | 0 |
Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Total Score Related to Overall Life Interference Assessed at Baseline, Using Dyad Clinical Outcomes Assessment 1 (DCOA 1) Questionnaire | 29.5 ± 18.0 | 27.1 ± 19.8 |
Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Total Score Related to Overall Life Interference Assessed at Week 12, Using DCOA 1 Questionnaire | 25.2 ± 17.3 | 7.1 ± 7.8 |
Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Total Score Related to Overall Life Interference Assessed at Week 24, Using DCOA 1 Questionnaire | 9.5 ± 13.3 | 23.0 ± 22.6 |
Participants were assessed for their treatment burden using DCOA 1 questionnaire completed by participant/caregiver dyads. The participant life interference questionnaire component of the DCOA 1 had 7 questions (life interference \[5 questions\]: a measure of life interference \[daily activities/social activities/leisure/night away from home/travel\]; life interference-changes to life routine \[1 question\]: a measure of how often changes are made to life routine; and life interference-bother of growth hormone \[GH\] injections \[1 question\]: a measure of how often the growth hormone injections cause bother) and all questions used a 5-point scale: 1= never, 2= rarely, 3= sometimes, 4= often, 5= always. The overall life interference total score was sum of all 7 questions, scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant less life interference (better outcome).
| units on a scale | Genotropin | Somatrogon |
|---|---|---|
| Total Score Related to Overall Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire | 24.13 (20.61 to 27.65) | 8.63 (5.05 to 12.22) |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked 5 questions from Section I of the Injection Pen Assessment Questionnaire (IPAQ) patient-reported outcome (PRO) tool related to pen ease of use and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to pen ease of use was sum of all 5 questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline | 10.6 ± 11.3 | 11.6 ± 12.8 |
| Week 12 | 12.0 ± 13.8 | 5.1 ± 7.6 |
| Week 24 | 5.5 ± 9.3 | 9.4 ± 13.0 |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked 5 questions from Section I of the IPAQ PRO tool related to pen ease of use and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to pen ease of use was sum of all 5 questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
| units on a scale | Genotropin | Somatrogon |
|---|---|---|
| Total Score Related to Pen Ease of Use by Treatment in Overall Study, Using DCOA 1 Questionnaire | 10.71 (8.27 to 13.14) | 5.32 (2.84 to 7.80) |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to ease of the injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline | 18.5 ± 20.0 | 16.3 ± 17.5 |
| Week 12 | 23.3 ± 25.2 | 4.4 ± 11.2 |
| Week 24 | 9.5 ± 18.3 | 17.9 ± 22.3 |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 5-point scale: 1= very easy, 2= somewhat easy, 3= neither easy nor difficult, 4= somewhat difficult, 5= very difficult. The total score related to ease of the injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
| units on a scale | Genotropin | Somatrogon |
|---|---|---|
| Total Score Related to Ease of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire | 20.56 (16.22 to 24.89) | 6.96 (2.54 to 11.37) |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 7-point scale: 1=extremely convenient to 7=extremely inconvenient. The total score related to convenience of injection schedule ranged from 1 to 7; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline | 34.5 ± 21.0 | 32.5 ± 21.3 |
| Week 12 | 35.3 ± 23.9 | 7.9 ± 10.7 |
| Week 24 | 11.9 ± 14.4 | 33.3 ± 24.1 |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to ease of injection schedule and used a 7-point scale: 1=extremely convenient to 7=extremely inconvenient. The total score related to convenience of injection schedule ranged from 1 to 7; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
| units on a scale | Genotropin | Somatrogon |
|---|---|---|
| Total Score Related to Convenience of the Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire | 34.30 (30.13 to 38.47) | 9.96 (5.71 to 14.21) |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant satisfaction with treatment and used a 5-point scale: 1=very satisfied to 5=very dissatisfied. The total score related to satisfaction with overall treatment ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline | 28.0 ± 21.5 | 29.4 ± 23.3 |
| Week 12 | 27.3 ± 27.2 | 20.0 ± 31.1 |
| Week 24 | 22.0 ± 32.3 | 30.4 ± 27.9 |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant satisfaction with treatment and used a 5-point scale: 1=very satisfied to 5=very dissatisfied. The total score related to satisfaction with overall treatment ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
| units on a scale | Genotropin | Somatrogon |
|---|---|---|
| Total Score Related to Satisfaction With Overall Treatment Experience by Treatment in Overall Study, Using DCOA 1 Questionnaire | 28.95 (22.55 to 35.36) | 21.13 (14.61 to 27.65) |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant willingness to continue treatment and used a 5-point scale: 1=extremely willing to 5=not at all willing. The total score related to willingness to continue injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline | 18.5 ± 20.0 | 22.5 ± 23.9 |
| Week 12 | 28.5 ± 27.6 | 10.6 ± 21.1 |
| Week 24 | 13.1 ± 24.8 | 30.4 ± 29.0 |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to participant willingness to continue treatment and used a 5-point scale: 1=extremely willing to 5=not at all willing. The total score related to willingness to continue injection schedule ranged from 1 to 5; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score meant a better outcome.
| units on a scale | Genotropin | Somatrogon |
|---|---|---|
| Total Scores Related to Willingness to Continue Injection Schedule by Treatment in Overall Study, Using DCOA 1 Questionnaire | 29.54 (23.95 to 35.12) | 11.93 (6.24 to 17.62) |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participants (8-17 years old). Participants were asked 4 questions from Section I of the IPAQ PRO tool related to participant's injection signs and symptoms and used a 11-point scale: 0=no pain to 10=worst possible pain; 0=no stinging to 10=worst possible stinging; 0=no bruising to 10=worst possible bruising; and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for injection signs and symptoms meant a better outcome.
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline | 15.0 ± 10.4 | 13.8 ± 11.9 |
| Week 12 | 16.2 ± 12.2 | 13.7 ± 10.3 |
| Week 24 | 13.6 ± 12.2 | 10.9 ± 9.6 |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participants (8-17 years old). Participants were asked 4 questions from Section I of the IPAQ PRO tool related to participant's injection signs and symptoms and used a 11-point scale: 0=no pain to 10=worst possible pain; 0=no stinging to 10=worst possible stinging; 0=no bruising to 10=worst possible bruising; and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for injection signs and symptoms meant a better outcome.
| units on a scale | Genotropin | Somatrogon |
|---|---|---|
| Total Scores Related to Injection Signs and Symptoms for Participants Aged 8 Years and Above by Treatment in Overall Study, Using DCOA 1 Questionnaire | 13.56 (10.78 to 16.34) | 14.27 (11.32 to 17.21) |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver for children under 8 years. Participants were asked 2 questions from Section I of the IPAQ PRO tool related to participant's assessment of signs and used a 11-point scale: 0=no bruising to 10=worst possible bruising and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for assessment of signs meant a better outcome.
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline | 14.2 ± 14.6 | 13.5 ± 11.3 |
| Week 12 | 9.3 ± 10.6 | 13.0 ± 15.8 |
| Week 24 | 5.6 ± 7.8 | 9.4 ± 8.8 |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver for children under 8 years. Participants were asked 2 questions from Section I of the IPAQ PRO tool related to participant's assessment of signs and used a 11-point scale: 0=no bruising to 10=worst possible bruising and 0=no bleeding to 10=worst possible bleeding, respectively. The total score was sum of all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for assessment of signs meant a better outcome.
| units on a scale | Genotropin | Somatrogon |
|---|---|---|
| Total Scores Related to Assessment of Signs, Completed by Caregiver for Children Aged <8 Years by Treatment in Overall Study, Using DCOA 1 Questionnaire | 8.75 (2.65 to 14.86) | 9.31 (3.47 to 15.16) |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver. Participants were asked 13 questions from Section I of the IPAQ PRO tool related to caregiver life interference and used a 5-point scale: 1= never to 5= always. The total score ranged was sum of scores from all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for caregiver and family life interference meant less life interference (a better outcome).
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline | 17.8 ± 17.5 | 20.0 ± 20.1 |
| Week 12 | 15.9 ± 16.7 | 3.1 ± 5.5 |
| Week 24 | 3.8 ± 6.0 | 18.1 ± 23.4 |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by caregiver. Participants were asked 13 questions from Section I of the IPAQ PRO tool related to caregiver life interference and used a 5-point scale: 1= never to 5= always. The total score ranged was sum of scores from all questions; scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for caregiver and family life interference meant less life interference (a better outcome).
| units on a scale | Genotropin | Somatrogon |
|---|---|---|
| Total Scores Related to Caregiver Life Interference, Including Family Life Interference by Treatment in Overall Study, Using DCOA 1 Questionnaire | 17.01 (13.77 to 20.25) | 3.54 (0.24 to 6.84) |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to number of missed injections (daily or weekly administration) during past 4 weeks. The total scores ranged from 0 to 31 for daily administration (Genotropin) and from 0 to 5 for weekly administration (Somatrogon). All scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for missed injections meant a better outcome.
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline | 7.8 ± 15.1 | 7.3 ± 16.1 |
| Week 12 | 4.3 ± 8.2 | 0.0 ± 0.0 |
| Week 24 | 1.9 ± 7.4 | 3.1 ± 10.8 |
Participants were assessed for their treatment experience using DCOA 1 questionnaire completed by participant/caregiver dyads. Participants were asked a question from Section I of the IPAQ PRO tool related to number of missed injections (daily or weekly administration) during past 4 weeks. The total scores ranged from 0 to 31 for daily administration (Genotropin) and from 0 to 5 for weekly administration (Somatrogon). All scores were transformed from raw scores and converted to a 0 to 100 scale; a lower score for missed injections meant a better outcome.
| units on a scale | Genotropin | Somatrogon |
|---|---|---|
| Total Scores Related to Missed Injections by Treatment in Overall Study, Using DCOA 1 Questionnaire | 3.71 (2.03 to 5.39) | 0.95 (-0.76 to 2.66) |
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "If you were given the choice between the daily growth hormone injection pen and the weekly growth hormone injection pen, which pen would you choose?" Response was: 1) the daily injection pen (Genotropin) or 2) the weekly injection pen (Somatrogon).
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Somatrogon | 38 | 36 |
| Genotropin | 4 | 6 |
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule do you prefer overall?" by choosing from any 1 option from: 1) prefer the weekly injection schedule (Somatrogon); 2) prefer the daily injection schedule (Genotropin); 3) no preference.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Somatrogon | 40 | 37 |
| Genotropin | 2 | 4 |
| No Preference | 0 | 1 |
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule was more convenient overall?" by choosing from any 1 option from: 1) weekly injection schedule was more convenient (Somatrogon); 2) daily injection schedule was more convenient (Genotropin); 3) no difference.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Somatrogon | 40 | 40 |
| Genotropin | 2 | 2 |
| No Difference | 0 | 0 |
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregivers responded to question from Section II of the IPAQ PRO tool "Which growth hormone injection schedule was easier to follow overall?" by choosing from any 1 option from: 1) easier to follow weekly injection schedule (Somatrogon); 2) easier to follow daily injection schedule (Genotropin); 3) no difference.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Somatrogon | 38 | 34 |
| Genotropin | 4 | 4 |
| No Difference | 0 | 4 |
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "Which pen was easier to use?" from Section II of the IPAQ PRO tool. Question had 4 parts: preparing the injection pen (Part I), setting the dose (Part II), injecting the medicine (Part III) and storing the pen (Part IV). Participants/caregiver expressed their preference by choosing from any 1 option for each activity from: 1) weekly pen easier to use (Somatrogon); 2) daily pen easier to use (Genotropin); 3) no difference.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Part I: Somatrogon | 29 | 25 |
| Part I: Genotropin | 3 | 4 |
| Part I: No difference | 10 | 13 |
| Part II: Somatrogon | 21 | 17 |
| Part II: Genotropin | 6 | 8 |
| Part II: No Difference | 15 | 17 |
| Part III: Somatrogon | 13 | 18 |
| Part III: Genotropin | 16 | 12 |
| Part III: No Difference | 13 | 12 |
| Part IV: Somatrogon | 12 | 14 |
| Part IV: Genotropin | 2 | 2 |
| Part IV: No Difference | 28 | 26 |
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to participant life interference. Participants were assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). The participants expressed their preference by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Activity 1: Somatrogon | 35 | 31 |
| Activity 1: Genotropin | 2 | 1 |
| Activity 1: No Difference | 5 | 10 |
| Activity 2: Somatrogon | 34 | 34 |
| Activity 2: Genotropin | 2 | 0 |
| Activity 2: No Difference | 6 | 8 |
| Activity 3: Somatrogon | 34 | 33 |
| Activity 3: Genotropin | 2 | 1 |
| Activity 3: No Difference | 6 | 8 |
| Activity 4: Somatrogon | 36 | 37 |
| Activity 4: Genotropin | 2 | 1 |
| Activity 4: No Difference | 4 | 4 |
| Activity 5: Somatrogon | 33 | 37 |
| Activity 5: Genotropin | 3 | 0 |
| Activity 5: No Difference | 6 | 5 |
Caregivers of participants were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to caregiver life interference and were assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). Preference was expressed by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference. The caregivers responded for the participants, and in actual they respond to the number of participants only but per caregiver responses.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Activity 1: Somatrogon | 36 | 31 |
| Activity 1: Genotropin | 2 | 0 |
| Activity 1: No Difference | 4 | 11 |
| Activity 2: Somatrogon | 36 | 32 |
| Activity 2: Genotropin | 2 | 0 |
| Activity 2: No Difference | 4 | 10 |
| Activity 3: Somatrogon | 35 | 34 |
| Activity 3: Genotropin | 2 | 0 |
| Activity 3: No Difference | 5 | 8 |
| Activity 4: Somatrogon | 35 | 37 |
| Activity 4: Genotropin | 1 | 0 |
| Activity 4: No Difference | 6 | 5 |
| Activity 5: Somatrogon | 35 | 37 |
| Activity 5: Genotropin | 2 | 0 |
| Activity 5: No Difference | 5 | 5 |
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/ caregiver were asked a question "Which injection schedule interfered less?" from Section II of the IPAQ PRO tool related to family life interference and assessed for 5 activities: daily activities (Activity 1), social activities (Activity 2), recreation/leisure activities (Activity 3), spending night away from home (Activity 4) and travel (Activity 5). Preference was expressed by choosing from any 1 option for each activity from: 1) weekly injection schedule interfered less (Somatrogon); 2) daily injection schedule interfered less (Genotropin); 3) no difference.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Activity 1: Somatrogon | 32 | 29 |
| Activity 1: Genotropin | 1 | 0 |
| Activity 1: No Difference | 9 | 13 |
| Activity 2: Somatrogon | 32 | 30 |
| Activity 2: Genotropin | 1 | 0 |
| Activity 2: No Difference | 9 | 12 |
| Activity 3: Somatrogon | 32 | 32 |
| Activity 3: Genotropin | 1 | 0 |
| Activity 3: No Difference | 9 | 10 |
| Activity 4: Somatrogon | 31 | 34 |
| Activity 4: Genotropin | 1 | 0 |
| Activity 4: No Difference | 10 | 8 |
| Activity 5: Somatrogon | 31 | 36 |
| Activity 5: Genotropin | 1 | 0 |
| Activity 5: No Difference | 10 | 6 |
Participants were assessed for their treatment experience using DCOA 2 questionnaire completed by participant/caregiver dyads. Participants/caregiver were asked a question "How beneficial was to take injections less often?" from Section II of the IPAQ PRO tool pertaining to benefit relating to the Injection schedule and used a 5-point scale: 1= extremely beneficial, 2= very beneficial, 3= moderately beneficial, 4= slightly beneficial and 5= not at all beneficial. Lower score of benefit relating to injection schedule meant a better outcome.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Extremely Beneficial | 28 | 20 |
| Very Beneficial | 11 | 14 |
| Moderately Beneficial | 1 | 3 |
| Slightly Beneficial | 0 | 3 |
| Not At All Beneficial | 2 | 2 |
Participants/caregiver dyads were asked 4 questions "Which schedule would be better able to follow?" (Question 1), "Which schedule would be more likely to follow for a longer time?" (Question 2), "Which schedule would be better able to follow for a longer time?" (Question 3) and "Which schedule would be more likely to follow?" (Question 4) from Section II of the IPAQ PRO tool related to participant intention to comply with treatment. Options for each question were: 1) weekly injection (Somatrogon) 2) daily injection (Genotropin), or 3) no difference.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Question 1: Somatrogon | 33 | 31 |
| Question 1: Genotropin | 2 | 2 |
| Question 1: No Difference | 7 | 9 |
| Question 2: Somatrogon | 29 | 32 |
| Question 2: Genotropin | 1 | 2 |
| Question 2: No Difference | 12 | 8 |
| Question 3: Somatrogon | 34 | 35 |
| Question 3: Genotropin | 1 | 1 |
| Question 3: No Difference | 7 | 6 |
| Question 4: Somatrogon | 26 | 31 |
| Question 4: Genotropin | 3 | 2 |
| Question 4: No Difference | 13 | 9 |
The PGIS-IDA rated the severity of the impact on daily activities due to the treatment administration during the past 4 weeks on a 7-point scale (1= not present to 7= extremely severe). Scores were transformed from raw scores to a 0 to 100 scale. Lower scores meant less impact on daily activities (better outcome).
| units on a scale | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline | 15.0 ± 14.8 | 16.3 ± 16.2 |
| Week 12 | 19.0 ± 19.4 | 4.6 ± 7.5 |
| Week 24 | 7.1 ± 9.8 | 22.2 ± 20.4 |
The PGIS-IDA rated the severity of the impact on daily activities due to the treatment administration during the past 4 weeks on a 7-point scale (1= not present to 7= extremely severe). Scores were transformed from raw scores to a 0 to 100 scale. Lower scores meant less impact on daily activities (better outcome).
| units on a scale | Genotropin | Somatrogon |
|---|---|---|
| Patient Global Impression Severity-Impact on Daily Activities (PGIS-IDA) Score by Treatment in Overall Study | 20.64 (17.30 to 23.99) | 6.06 (2.66 to 9.46) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Treatment-emergent AEs (TEAEs) were defined as events that occurred between first dose of study drug up to 35 days after last dose of study drug. Related TEAEs were those AEs who had relation to the study treatment and was judged by investigator.
| Participants | Genotropin | Somatrogon |
|---|---|---|
| Treatment-Emergent AEs | 38 | 47 |
| Treatment-Emergent SAEs | 0 | 0 |
| Treatment-Emergent Related AEs | 14 | 21 |
| Treatment-Emergent Related SAEs | 0 | 0 |
AEs were assessed and categorized according to the severity as mild (did not interfered with participant's usual function), moderate (interfered to some extent with participant's usual function) and severe (interfered significantly with participant's usual function).
| Participants | Genotropin | Somatrogon |
|---|---|---|
| Mild | 34 | 41 |
| Moderate | 4 | 6 |
| Severe | 0 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. The discontinuations due to adverse events was defined for participants and reported in this outcome measure.
| Participants | Genotropin | Somatrogon |
|---|---|---|
| Number of Participants With Discontinuation Due to Adverse Events (AEs) | 0 | 1 |
The laboratory abnormality parameters included Hematology: erythrocyte (Er.) mean corpuscular volume, Er. mean corpuscular hemoglobin:\<0.9\*lower limit normal (LLN), leukocytes:\<0.6\*LLN, lymphocytes:\<0.8\*LLN, neutrophils:\<0.8\*LLN, greater than (\>) 1.2\*upper limit normal (ULN), eosinophils, monocytes:\>1.2\*ULN. Clinical chemistry: bilirubin, direct bilirubin, indirect bilirubin:\>1.5\*ULN, gamma glutamyl transferase:\>3.0\*ULN, albumin:\>1.2\*ULN, blood urea nitrogen:\>1.3\*ULN, urate:\>1.2\*ULN, high-density lipoprotein (HDL) cholesterol:\<0.8\*LLN, potassium, magnesium:\>1.1\*ULN, phosphate:\>1.2\*ULN, bicarbonate:\<0.9\*LLN, creatine kinase:\>2.0\*ULN. Urinalysis: specific gravity:\>1.030, ketones, urine protein, urine hemoglobin, nitrite, leukocyte esterase:\>=1.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Week 1 to Week 12 | 19 | 19 |
| Week 13 to Week 24 | 24 | 21 |
Blood samples were collected for determination of rhGH and NAb. The participants who tested positive for antibodies were reported.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline: Anti-rhGH | 5 | 0 |
| Baseline: Neutralizing | 0 | 0 |
| Week 12: Anti-rhGH | 3 | 3 |
| Week 12: Neutralizing | 0 | 0 |
| Week 24: Anti-rhGH | 4 | 6 |
| Week 24: Neutralizing | 0 | 0 |
Blood samples were collected for determination of anti-somatrogon antibodies and NAb. The participants who tested positive for antibodies were reported.
| Participants | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin |
|---|---|---|
| Baseline: Anti-Somatrogon Antibodies | 0 | 0 |
| Baseline: Neutralizing | 0 | 0 |
| Week 12: Anti-Somatrogon Antibodies | — | 4 |
| Week 12: Neutralizing | — | 0 |
| Week 24: Anti-Somatrogon Antibodies | 0 | — |
| Week 24: Neutralizing | 0 | — |
Collected over Baseline up to 35 days after last dose of study drug (up to 29 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Genotropin | 0/86 (0%) | 0/86 (0%) | 38/86 (44.2%) |
| Somatrogon | 0/87 (0%) | 0/87 (0%) | 47/87 (54%) |
| Event | Genotropin | Somatrogon |
|---|---|---|
| Injection site painGeneral disorders | 11/86 | 13/87 |
| Injection site haematomaGeneral disorders | 8/86 | 4/87 |
| NasopharyngitisInfections and infestations | 5/86 | 6/87 |
| HeadacheNervous system disorders | 5/86 | 6/87 |
| PyrexiaGeneral disorders | 4/86 | 2/87 |
| Upper respiratory tract infectionInfections and infestations | 2/86 | 4/87 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/86 | 4/87 |
| Viral infectionInfections and infestations | 3/86 | 1/87 |
| Ear infectionInfections and infestations | 2/86 | 3/87 |
| Body temperature increasedInvestigations | 1/86 | 3/87 |
The safety analysis set included all participants who received at least 1 dose of study intervention. The participants were analyzed according to the intervention they actually received.
| Age, Continuous(Years) | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin | Total |
|---|---|---|---|
| Mean | 10.8 ± 3.4 | 10.7 ± 3.7 | 10.7 ± 3.5 |
| Sex: Female, Male(Participants) | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin | Total |
|---|---|---|---|
| Female | 9 | 6 | 15 |
| Male | 34 | 38 | 72 |
| Ethnicity (NIH/OMB)(Participants) | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 |
| Not Hispanic or Latino | 39 | 42 | 81 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Daily Genotropin Then Weekly Somatrogon | Weekly Somatrogon Then Daily Genotropin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 39 | 42 | 81 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2019 to primary completion in Aug 2020, 18 months.
Results were first posted in Oct 2021, 1 year 1 month after primary completion.
Of 19 phase 3 interventional studies under Dwarfism, Pituitary, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Human Growth Hormone · Somatrogon